Search results
Moderna’s sales from its only product, the COVID-19 vaccine, fell 91% from last year
Fortune via Yahoo Finance· 3 days agoModerna’s next focus is to continue rolling out mRNA vaccines, which teaches cells how to make the...
U.S. to start offering COVID-19 vaccine booster doses in September
AOL· 7 days agoThe White House is prepared to offer a third booster shot starting on that date to all Americans who...
Moderna loses less than expected as Covid vaccine sales beat estimates, cost cuts take hold
CNBC· 3 days agoModerna on Thursday posted a narrower-than-expected loss for the first quarter as the company's...
Moderna, Inc. (NASDAQ:MRNA) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 23 hours agoModerna, Inc. (NASDAQ:MRNA) Q1 2024 Earnings Call Transcript May 2, 2024 Moderna, Inc. beats...
Moderna stock surges 15% after it beat earnings expectations despite plummeting COVID vaccine sales
Quartz· 3 days agoModerna stock soared on Thursday after its first-quarter earnings report sailed past Wall Street’s...
Why Africa is facing an uphill battle to make its own vaccines
The Telegraph via Yahoo News· 4 days agoSouth African officials said that the decision to give a three-year contract to Indian generic...
Moderna reports $1.2bn net loss in Q1 2024
Pharmaceutical Technology via Yahoo Finance· 2 days agoNet product sales plummeted by 91% compared to Q1 2023. This downturn...transition to a seasonal market for Covid-19 vaccines. During Q1 2023, Moderna...
Thousands Believe Covid Vaccines Harmed Them. Is Anyone Listening?
New York Times· 2 days agoWithin minutes of getting the Johnson & Johnson Covid-19 vaccine, Michelle Zimmerman felt pain...
US opens COVID vaccine to little kids, shots begin next week
AOL· 6 days agoThe U.S. on Saturday opened COVID-19 vaccines to infants, toddlers and preschoolers. The shots will...
Moderna Reports First Quarter 2024 Financial Results and Provides Business Updates
Digital Journal· 3 days agoReports first quarter revenues of $167 million, GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)Prepares for launches of RSV vaccine and Spikevax® 2024-2025 formula ...